2013 Saw Many Advances in Cancer Care

2013 Saw Many Advances in Cancer Care

A new paper released by the American Society of Clinical Oncology, or ASCO, says that doctors and researchers like Anton Bilchik MD have made huge progress in cancer treatment over the past year. Published in the Journal of Clinical Oncology, the study names 76 advances in genomics, treatment-resistant cancers, and targeted immunotherapy that should give new hope to cancer patients.

Genomics research, which made big progress in 2013, helps doctors understand the genetic makeup of cancer. This will help doctors devise individualized treatment plans and drive drug development. The year 2013 also saw the introduction of therapies that work on treatment-resistant cancers. Scientists also unveiled targeted immunotherapy research, which harnesses the body’s own immune system to fight cancer.

Anton Bilchik MD had a productive year, as well. U.S. News and World Report named him among the top 1 percent of doctors in 2013. This cancer surgeon has now won this prestigious award for ten consecutive years.

Anton Bilchik MD also learned the John Wayne Cancer Institute will bestow the “The Duke” awards upon him in 2014. The medical institute will also honor the Mandela Family with the “True Grit” award at that ceremony.

Anton Bilchik MD earned these recognitions because of his work inside the surgical suite and outside of it. He is a highly sought-after speaker and well respected researcher. In 2013, he worked with other researchers to publish articles such as:

• AJCC Cancer Staging Manual 7th edition criteria for colon cancer: do the complex modifications improve prognostic assessment?
• Serum-based DNA methylation biomarkers in colorectal cancer: potential for screening and early detection
• Evidence-Based Guidelines for Precision Risk Stratification-Based Screening (PRSBS) for Colorectal Cancer: Lessons learned from the US Armed Forces: Consensus and Future Directions
• Colorectal cancer stem cells as biomarkers: Where it all starts?
• Tumor-infiltrating immune cells promoting tumor invasion and metastasis: existing theories
• Technical Effects of Adding 1 % Lidocaine to Technetium Sulfur Colloid for Sentinel Lymphatic Mapping in Early Breast Cancer: Analysis of Data from a Double-Blind Randomized Controlled Trial
• A 21-year analysis of stage I gallbladder carcinoma: is cholecystectomy alone adequate?
• Clinical decision support and individualized prediction of survival in colon cancer: Bayesian belief network model

Anton Bilchik MD looks forward to serving his nation-wide community in 2014, and thanks you for your support in 2013 and every year.